

909729

**Bullets prepared for Bob Nakagawa, Assistant Deputy Minister, Pharmaceutical Services
Division re: new oxycodone product, OxyNEO®.**

Not Responsive

S 13, S 17

Cc: Middlemiss, Maria HLTH:EX

Subject: Oxycodone

Hi All,

I've had a few doctors and one pharmacist mention recently on the phones that Oxycodone has been completely discontinued.

Is this true, and will we be changing any criteria because of this?

Thank you!

Linda Storey

Special Authority Technician
Special Authorizations
Pharmaceutical Services, Drug Intelligence
Ministry of Health
2-2, 1515 Blanshard Street
Victoria BC V8W 3C8
Phone: 250-952-2297
Fax: 250-952-2116
email linda.storey@gov.bc.ca



Please consider the environment before printing this e-mail

OXYCONTIN®
OXYCODONE HCl CONTROLLED-RELEASE TABLETS

OxyNEO®

February 21, 2012

For Discussion Only

Confidential



BRITISH
COLUMBIA

The Best Place on Earth

CONFIDENTIAL

Pages 4 through 7 redacted for the following reasons:

Not Responsive

OxyNEO Coverage Decisions

1. Existing Oxycontin users
2. New users
3. Generic oxycontin (available fall 2012)

CONFIDENTIAL



BRITISH
COLUMBIA

The Best Place on Earth

Pages 9 through 19 redacted for the following reasons:

Not Responsive

Generic oxy – will it lead to more abuse?

- Evidence that introduction of a generic opioid does not increase diversion risk
- However, not aware of evidence of impact of introducing generic without tamper resistant formulations; may theoretically have higher risk



Pages 21 through 29 redacted for the following reasons:

Not Responsive

OxyNEO Coverage Decisions

1. Existing Oxycontin users
2. New users
3. Generic oxycontin (available fall 2012)

CONFIDENTIAL



BRITISH
COLUMBIA

The Best Place on Earth

Pages 31 through 32 redacted for the following reasons:

Not Responsive

S13


3. Options – generic Oxycontin

Assumptions:

- ☐ Available in fall 2012
- ☐ Will NOT have tamper-resistant formulation

S. 13

CONFIDENTIAL



Page 34 redacted for the following reason:

Not Responsive

Not Responsive

From: Moneo, Mitch HLTH:EX
Sent: Thursday, February 23, 2012 9:20 AM
To: Lun, Eric HLTH:EX; Nakagawa, Bob HLTH:EX; Therrien, Darlene HLTH:EX
Cc: Taylor, Suzanne C HLTH:EX; Zimmerman, Janine HLTH:EX
Subject: RE: Ox Tail Soup

Yes. I think the way you have captured it in your notes reflects our decision and the rationale behind it.

Mitch Moneo
A/Executive Director, Business Management & Supplier Relations
Pharmaceutical Services Division
BC Ministry of Health
301-960 Quayside Drive
New Westminster BC V3M 6G2
Tel: (604) 660-0492
Victoria: (250) 952-2642
Blackberry: (250) 516-5274
Fax: (604) 660-5405
E-mail: mitch.moneo@gov.bc.ca

From: Lun, Eric HLTH:EX
Sent: Thursday, February 23, 2012 9:16 AM
To: Nakagawa, Bob HLTH:EX; Therrien, Darlene HLTH:EX
Cc: Taylor, Suzanne C HLTH:EX; Moneo, Mitch HLTH:EX; Zimmerman, Janine HLTH:EX
Subject: RE: Ox Tail Soup

Thanks all....Mitch - I haven't heard from you but I assume you're fine with it.

S13

Eric Lun, PharmD
Executive Director, Drug Intelligence Branch
Pharmaceutical Services Division, Ministry of Health

From: Nakagawa, Bob HLTH:EX
Sent: Thursday, February 23, 2012 8:41 AM
To: Therrien, Darlene HLTH:EX
Cc: Taylor, Suzanne C HLTH:EX; Lun, Eric HLTH:EX; Moneo, Mitch HLTH:EX; Zimmerman, Janine HLTH:EX
Subject: Re: Ox Tail Soup

That all makes sense to me. We'll need to update the issues note ASAP

Thanks Eric.

B

Bob Nakagawa, ADM
BC Ministry of Health
250.952.1705

On Feb 23, 2012, at 7:09 AM, "Therrien, Darlene HLTH:EX" <Darlene.Therrien@gov.bc.ca> wrote:

Agreed with Suzanne.

Darlene

On 2012-02-23, at 7:05 AM, "Taylor, Suzanne C HLTH:EX" <Suzanne.Taylor@gov.bc.ca> wrote:

One thing I would like to fully understand...

S13

Otherwise, it looks good to me.

Thanks, Suz

From: Lun, Eric HLTH:EX
Sent: Wed, February 22, 2012 10:54 PM
To: Nakagawa, Bob HLTH:EX; Taylor, Suzanne C HLTH:EX; Moneo, Mitch HLTH:EX; Therrien, Darlene HLTH:EX
Cc: Zimmerman, Janine HLTH:EX
Subject: Ox Tail Soup
Importance: High

Hi there - We were a bit rushed at the end so I would like to recap the decisions, reasons and certain implementation steps. Please review ASAP.

Not Responsive

Not Responsive

4. Generic (when available)

S13

S13

Reasons:

Not Responsive

5. Generic ox coming and new ox would be significant premium

Not Responsive

Eric Lun, PharmD

Executive Director, Drug Intelligence Branch

